Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer

Florent Mouliere, Safia El Messaoudi, Dalong Pang, Anatoly Dritschilo, Alain R. Thierry

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Development of a Q-PCR-based assay for the high-performance analysis of circulating cell-free DNA (ccfDNA) requires good knowledge of its structure and size.In this work, we present the first visual determination of ccfDNA by Atomic Force Microscopy (AFM) on plasma samples from colorectal cancer (CRC) patients and healthy donors. In addition to the examination of fragment size distribution profile as performed by Q-PCR, this analysis confirms that ccfDNA is highly fragmented and that more than 80% of ccfDNA fragments in CRC plasma are below 145 bp. We adapted an Allele-Specific Blocker (ASB) Q-PCR to small ccfDNA fragments to determine simultaneously the total ccfDNA concentration, the presence of point mutation, the proportion of mutated allele, and a ccfDNA integrity index. The data validated analytically these four parameters in 124 CRC clinical samples and 71 healthy individuals. The multi-marker method, termed Intplex, enables sensitive and specific non-invasive analysis of tumor ccfDNA, which has great potential in terms of cost, quality control, and easy implementation in every clinical center laboratory.

Original languageEnglish
Pages (from-to)927-941
Number of pages15
JournalMolecular oncology
Volume8
Issue number5
DOIs
Publication statusPublished - 1 Jan 2014

Cite this

Mouliere, Florent ; El Messaoudi, Safia ; Pang, Dalong ; Dritschilo, Anatoly ; Thierry, Alain R. / Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. In: Molecular oncology. 2014 ; Vol. 8, No. 5. pp. 927-941.
@article{4eaaf902d5ed4470bafe07c225eda336,
title = "Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer",
abstract = "Development of a Q-PCR-based assay for the high-performance analysis of circulating cell-free DNA (ccfDNA) requires good knowledge of its structure and size.In this work, we present the first visual determination of ccfDNA by Atomic Force Microscopy (AFM) on plasma samples from colorectal cancer (CRC) patients and healthy donors. In addition to the examination of fragment size distribution profile as performed by Q-PCR, this analysis confirms that ccfDNA is highly fragmented and that more than 80{\%} of ccfDNA fragments in CRC plasma are below 145 bp. We adapted an Allele-Specific Blocker (ASB) Q-PCR to small ccfDNA fragments to determine simultaneously the total ccfDNA concentration, the presence of point mutation, the proportion of mutated allele, and a ccfDNA integrity index. The data validated analytically these four parameters in 124 CRC clinical samples and 71 healthy individuals. The multi-marker method, termed Intplex, enables sensitive and specific non-invasive analysis of tumor ccfDNA, which has great potential in terms of cost, quality control, and easy implementation in every clinical center laboratory.",
keywords = "Circulating cell-free DNA, Colorectal cancer, Multi-marker analysis, qPCR",
author = "Florent Mouliere and {El Messaoudi}, Safia and Dalong Pang and Anatoly Dritschilo and Thierry, {Alain R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.molonc.2014.02.005",
language = "English",
volume = "8",
pages = "927--941",
journal = "Molecular oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "5",

}

Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. / Mouliere, Florent; El Messaoudi, Safia; Pang, Dalong; Dritschilo, Anatoly; Thierry, Alain R.

In: Molecular oncology, Vol. 8, No. 5, 01.01.2014, p. 927-941.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer

AU - Mouliere, Florent

AU - El Messaoudi, Safia

AU - Pang, Dalong

AU - Dritschilo, Anatoly

AU - Thierry, Alain R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Development of a Q-PCR-based assay for the high-performance analysis of circulating cell-free DNA (ccfDNA) requires good knowledge of its structure and size.In this work, we present the first visual determination of ccfDNA by Atomic Force Microscopy (AFM) on plasma samples from colorectal cancer (CRC) patients and healthy donors. In addition to the examination of fragment size distribution profile as performed by Q-PCR, this analysis confirms that ccfDNA is highly fragmented and that more than 80% of ccfDNA fragments in CRC plasma are below 145 bp. We adapted an Allele-Specific Blocker (ASB) Q-PCR to small ccfDNA fragments to determine simultaneously the total ccfDNA concentration, the presence of point mutation, the proportion of mutated allele, and a ccfDNA integrity index. The data validated analytically these four parameters in 124 CRC clinical samples and 71 healthy individuals. The multi-marker method, termed Intplex, enables sensitive and specific non-invasive analysis of tumor ccfDNA, which has great potential in terms of cost, quality control, and easy implementation in every clinical center laboratory.

AB - Development of a Q-PCR-based assay for the high-performance analysis of circulating cell-free DNA (ccfDNA) requires good knowledge of its structure and size.In this work, we present the first visual determination of ccfDNA by Atomic Force Microscopy (AFM) on plasma samples from colorectal cancer (CRC) patients and healthy donors. In addition to the examination of fragment size distribution profile as performed by Q-PCR, this analysis confirms that ccfDNA is highly fragmented and that more than 80% of ccfDNA fragments in CRC plasma are below 145 bp. We adapted an Allele-Specific Blocker (ASB) Q-PCR to small ccfDNA fragments to determine simultaneously the total ccfDNA concentration, the presence of point mutation, the proportion of mutated allele, and a ccfDNA integrity index. The data validated analytically these four parameters in 124 CRC clinical samples and 71 healthy individuals. The multi-marker method, termed Intplex, enables sensitive and specific non-invasive analysis of tumor ccfDNA, which has great potential in terms of cost, quality control, and easy implementation in every clinical center laboratory.

KW - Circulating cell-free DNA

KW - Colorectal cancer

KW - Multi-marker analysis

KW - qPCR

UR - http://www.scopus.com/inward/record.url?scp=84903549166&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2014.02.005

DO - 10.1016/j.molonc.2014.02.005

M3 - Article

VL - 8

SP - 927

EP - 941

JO - Molecular oncology

JF - Molecular oncology

SN - 1574-7891

IS - 5

ER -